This study underscores the potential of IV ketamine in managing major depressive disorder, especially in patients with a history of multiple antidepressant trials. With a significant percentage achieving response or remission within six weeks, and these benefits sustained over months, ketamine offers a promising avenue for chronic depression management.

Groundbreaking research reveals ketamine’s potential as an effective alternative to ECT in treating treatment-resistant depression, offering new hope to millions.

The FDA’s recent warning about compounded ketamine products underscores the need for rigorous clinical studies to investigate ketamine’s benefit-risk profile and safe-use conditions in the treatment of psychiatric disorders.

Despite the potential benefits of ketamine in treating a range of neurological and psychiatric disorders, the FDA has issued warnings about the potential risks associated with its use, emphasizing the need for careful prescription and clinical oversight.

Stay abreast of the latest developments in patient care. Learn more about the FDA’s recent warning on the potential risks associated with compounded ketamine products used for treating psychiatric disorders.

Discover how esketamine nasal spray could significantly alter the treatment approach for patients suffering from treatment-resistant depression.